In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction

Vishal N. Rao, Evan Murray, Javed Butler, Lauren B. Cooper, Zachary L. Cox, Mona Fiuzat, Jennifer B. Green, Jo Ann Lindenfeld, Darren K. McGuire, Michael E. Nassif, Cara O'Brien, Neha Pagidipati, Kavita Sharma, Muthiah Vaduganathan, Orly Vardeny, Gregg C. Fonarow, Robert J. Mentz, Stephen J. Greene

Research output: Contribution to journalReview articlepeer-review

52 Scopus citations

Abstract

Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on blood pressure, and no excess risk of adverse kidney events. There is no evidence to suggest that deferring initiation to the outpatient setting accomplishes anything beneficial. Instead, there is compelling evidence that deferring in-hospital initiation exposes patients to excess risk of early postdischarge clinical worsening and death. Lessons from other heart failure with reduced ejection fraction therapies highlight that deferring initiation of guideline-recommended medications to the U.S. outpatient setting carries a >75% chance they will not be initiated within the next year. Recognizing that 1 in 4 patients hospitalized for worsening heart failure die or are readmitted within 30 days, clinicians should embrace the in-hospital period as an optimal time to initiate sodium-glucose cotransporter-2 inhibitor therapy and treat this population with the urgency it deserves.

Original languageEnglish (US)
Pages (from-to)2004-2012
Number of pages9
JournalJournal of the American College of Cardiology
Volume78
Issue number20
DOIs
StatePublished - Nov 16 2021

Bibliographical note

Funding Information:
This paper summarizes proceedings of an independently organized academic meeting supported by an unrestricted educational grant from AstraZeneca. AstraZeneca did not have any role in the design, interpretation, or submission of the paper’s content. Dr Rao has been supported by a National Institutes of Health (NIH) Training Grant (NIH 5T32HL069749-17). Dr Butler has served as a consultant for Boehringer Ingelheim, Cardior, CVRx, Foundry, G3 Pharma, Imbria, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sanofi, Sequana Medical, V-Wave Ltd., and Vifor. Dr Cooper has received consulting fees from AstraZeneca; and has received research support from Abbott. Dr Cox has received research support from AstraZeneca. Dr Green has received research support from Boehringer Ingelheim/Lilly, Merck, Roche and Sanofi/Lexicon; and has received consulting fees from AstraZeneca, Boehringer Ingelheim/Lilly, Hawthorne Effect/Omada, NovoNordisk, and Pfizer. Dr Lindenfeld has received research support from AstraZeneca, Sensible Medical, and Volumetrix; and has received consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Boston Scientific, CVRx, Cytokinetics, Edwards Lifesciences, Impulse Dynamics, V-Wave, and Vifor. Dr McGuire has received honoraria for clinical trial leadership from Boehringer Ingelheim, Sanofi, AstraZeneca, Merck & Co, Pfizer, Novo Nordisk, Esperion, Lilly USA, Lexicon, and CSL Behring; and has received honoraria for consultancy from Lilly USA, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Applied Therapeutics, Metavant, Sanofi, Afimmune, and Lexicon. Dr Pagidipati has received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Regeneron, Sanofi, and Verily Life Sciences; and has received consulting fees from Boehringer Ingelheim, Eli Lilly, AstraZeneca, and Novo Nordisk. Dr Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, and Relypsa; has speaker engagements for Novartis; and has participated on clinical endpoint committees for studies sponsored by Galmed, Novartis, and NIH. Dr Fonarow served as a consultant for Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Janssen, Medtronic, Merck, and Novartis. Dr Mentz has received research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim/Eli Lilly, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Medtronic, Merck, Novartis, Relypsa, Respicardia, Roche, Sanofi, Vifor, and Windtree Therapeutics. Dr Greene has received research support from the Duke University Department of Medicine Chair’s Research Award, American Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, and Pfizer; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, and Cytokinetics; and has served as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, and Vifor. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publisher Copyright:
© 2021 American College of Cardiology Foundation

Keywords

  • guideline-directed medical therapy
  • heart failure
  • in-hospital prescribing
  • medical therapy
  • sodium-glucose cotransporter-2 inhibitors

Fingerprint

Dive into the research topics of 'In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction'. Together they form a unique fingerprint.

Cite this